Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
View Patent ↗A formulation, especially one that is topically administered, comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease.
1. A composition for oral administration comprising a combination of rapamycin and metformin, wherein the rapamycin is present in an amount in a range of about 0.15 mg to about 3.0 mg and metformin is present in an amount in a range of about 100 mg to about 900 mg.
2. The composition of claim 1 , wherein the rapamycin is present in an amount in a range of about 0.3 mg to about 2.0 mg and the metformin in present in an amount in a range of about 300 mg to about 600 mg.
3. The composition of claim 1 , wherein the rapamycin in present in an amount of up to about 2.0 mg and the metformin is present in an amount of up to about 800 mg.
4. The composition of claim 1 , wherein the amount of rapamycin is less than about 1 mg.
5. The composition of claim 1 , wherein the amount of metformin is less than about 600 mg.
6. The composition of claim 1 , wherein the composition is formulated for oral administration in a form selected from a tablet, a caplet, a capsule, and a liquid.
7. A method for treating or preventing, in a patient in need thereof, a vascular, inflammatory, neurologic, or neoplastic disorder associated with mTORC1 activation comprising:
administering an effective amount of a composition for oral administration comprising a combination of rapamycin and metformin, wherein the rapamycin is present in an amount in a range of about 0.1 mg to about 2.5 mg and metformin is present in an amount in a range of about 100 mg to about 1000 mg.
8. The method of claim 7 , wherein the inflammatory disorder is an autoimmune and/or immunologically mediated inflammatory disorder.
9. The method of claim 8 , wherein the autoimmune and/or immunologically mediated inflammatory disorder is selected from the group consisting of atopic dermatitis; inflammatory skin disease; inflammatory bowel disease; celiac disease; inflammatory airway disease; autoantibody-mediated autoimmune disease; inflammatory arthritis; neuroinflammatory disorder; discoid lupus; systemic lupus (SLE); sarcoidosis; uveitis; pemphigus vulgaris, renal transplantation, and graft vs. host disease.
10. The method of claim 8 , wherein the composition is administered to a patient being treated with at least one cancer immunotherapy agent.
11. The method of claim 7 , wherein the vascular disease is selected from rosacea; port wine stains; arteriovenous malformations; vascular ectasias; and cutaneous vascular lesions.
12. The method of claim 7 , wherein the neoplastic disorder is selected from Tuberous Sclerosis Complex (TSC); breast cancer; renal cell carcinoma; sarcomas including Kaposi's sarcoma; hepatocellular carcinoma; lymphomas; and neuroendocrine tumors (NETs).
13. The method of claim 7 , wherein the method of treating or preventing comprises halting or slowing the progression of a vascular, inflammatory, or neoplastic disorder associated with mTORC1 activation.
14. The method of claim 7 , wherein the method of treating or preventing comprises administering the composition to a patient at risk for developing or at risk for a recurrence of a vascular, inflammatory, neurologic, or neoplastic disorder associated with mTORC1 activation.
15. The method of claim 7 wherein the rapamycin is present in an amount in a range of about 0.1 mg to about 2.0 mg and the metformin in present in an amount in a range of about 150 mg to about 900 mg.
16. The method of claim 7 , wherein the rapamycin in present in an amount of up to about 2.0 mg and the metformin is present in an amount of up to about 500 mg.
17. The method of claim 7 , wherein the rapamycin in present in an amount of up to about 2.0 mg and the metformin is present in an amount of up to about 1000 mg.
18. The method of claim 7 , wherein the amount of rapamycin is less than about 1 mg.
19. The method of claim 7 , wherein the amount of metformin is less than about 600 mg.
20. The method of claim 7 , wherein the composition is formulated for oral administration in a form selected from a tablet, a caplet, a capsule, and a liquid.
21. The method of claim 7 , wherein the composition is administered daily.
22. The composition of claim 1 , wherein the composition is a daily oral composition.
23. The composition of claim 1 , wherein the composition achieves an in vivo molar ratio of rapamycin to metformin in the range of about 20:1 to about 1:1.